American Cancer Society recommends biennial PSA screening for most men aged 50 to 69
Juste les faits

American Cancer Society recommends biennial PSA screening for most men aged 50 to 69

Résumé

The American Cancer Society's new guidelines call for men aged 50-69 to receive a prostate-specific antigen test every two years, with annual testing for higher-risk groups and individualized decisions for men 70-74.

The American Cancer Society (ACS) updated its prostate-cancer screening recommendations, advising men aged 50 to 69 to undergo a prostate-specific antigen (PSA) blood test every other year. Men considered at higher risk – including Black men and those with close family members diagnosed before age 65 – should be screened annually. For men aged 70 to 74, the ACS suggests discussing the benefits and drawbacks of PSA testing with a health-care provider based on overall health and life expectancy.

The revised guidance, published in CA: A Cancer Journal for Clinicians, reflects recent evidence that regular PSA screening can reduce deaths from prostate cancer among middle-aged men. Dr. William L. Dahut, chief scientific officer of the ACS, said the aim is to increase screening for average-risk men and ultimately lower rates of metastatic disease while limiting unnecessary harm.

Previous ACS recommendations emphasized shared decision-making for men aged 40 to 50 with at least a decade of expected life. The new guidelines replace that approach with a clearer recommendation for biennial testing after age 50, while maintaining annual testing for the two higher-risk groups.

Prostate cancer remains the second-leading cause of cancer death among men in the United States. Although mortality has fallen by about 50 % over the past three decades, the decline has slowed for men aged 55 to 69, and diagnoses of advanced disease have risen roughly 6 % per year in that age group since 2014.

The ACS noted that earlier European studies with long-term follow-up have shown PSA screening can lower prostate-cancer mortality, prompting confidence in the updated recommendations. The organization also highlighted advances in diagnostic and treatment practices that help reduce the side effects associated with surgery and radiation.

Experts not involved in drafting the guidelines, such as Dr. Daniel George of Duke Health, emphasized that while cancer can provoke strong emotional reactions, improvements in therapy have increased survival rates for many patients.

The new guidance arrives amid ongoing debate over the balance between early detection and the risk of overdiagnosis, false-positive results, and treatment-related complications such as sexual dysfunction and urinary incontinence.

Source

NBC News

Continuez à lire — gratuitement

Créez un compte gratuit pour suivre l'actualité. Aucune carte requise.